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Accepted 26 June 2019; Published online 2 July 2019AbstractObjectives: Core outcome set (COS) development often begins with a systematic review to identify outcomes. Reviews frequently
show heterogeneity in numbers of outcomes reported across trials. Contributing to this is a lack of a uniform definition for an outcome.
This study proposes a first working definition for a unique trial outcome to support reporting a quantitative assessment of outcome reporting
heterogeneity (ORH).
Study Design and Setting: Eligible COS literature (development papers, protocols, and reviews) were identified using the COMET
database, Ovid MEDLINE, and PubMed. Outcome numbers, definitions, timing, and grouping methodology were examined.
Results: One hundred and thirty two studies were included. 82 (88.1%) studies (excluding protocols) reported a total number of unique
outcomes (median, 82; range, 12-5776; IQR, 261). Timing of assessment was reported in 32 (31.4%) studies. Methods to group similar
outcomes were reported in 8 (7.8%) articles. No study defined how outcomes were agreed as different and how final numbers of unique
outcomes were determined. It is proposed that a unique outcome requires original meaning and context. Thus ORH is suggested to be the
reporting of multiple unique outcomes across trials related to one health care condition.
Conclusion: This review identified inconsistencies in how authors define, extract, group, and count trial outcomes. Further work is needed
to refine our proposed definitions to optimize COS development and allow a quantifiable measure of ORH. Crown Copyright  2019 Pub-
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Well-designed and -conducted randomized controlled
trials (RCTs) determine effectiveness through an unbiased
comparison of outcomes (events or endpoints) by the inter-
vention group [1]. The choice and selection of outcomes is
critical in the RCT design, and trials may be regarded to be
‘‘only as credible as their outcomes’’ [2,3]. Trial outcomes,
however, may be defined in various ways, including [4e10]
‘‘as variables that are monitored during a study to docu-
ment the impact that a given intervention or exposure has
on the health of a given population’’ [11] and ‘‘as a variable
measured at a specific time point to assess the efficacy or
harm of an intervention’’ [12]. While these definitionsccess article under the CC BY-NC-ND license (http://creativecommons.org/
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Key findings
 Proposed definition of a unique outcome: ‘‘a trial
outcome is one that has original meaning and
context. Outcomes with different words, phrasing,
or spelling addressing the same concept and
context should be categorized as one outcome.’’
 Proposed definition of outcome reporting heteroge-
neity (ORH): ‘‘the reporting of multiple unique
outcomes across trials within one health care con-
dition’’ relates directly to and is dependent on the
definition of a unique outcome.
What this adds to what was known?
 This study analyzes current methods for identi-
fying, extracting, defining, grouping, and counting
outcomes into unique outcomes to inform core
outcome set (COS) development and allow the
quantitative reporting of ORH.
What is the implication and what should change
now?
 COS developers will ultimately have an objective
basis for accurately counting unique outcomes
across health care trials. This will allow the repro-
ducible quantitative measurement of ORH, inform
trial design, and ultimately inform evidence syn-
thesis and reduce research waste.
 Future collaborative work will be undertaken to
agree and to explore the validity of the final
definitions.
explain the role of an outcome in a trial, they do not define
what an outcome is per se. Other authors have examined the
completeness of outcome reporting using four or five
levels. These include outcome, measurement, metric, ag-
gregation of outcomes, and timing of measurement
[13,14]. Other work by Page and Dwan discusses the
completeness of outcome reporting. None of these articles
describe how to determine what makes an outcome unique
[12,15]. Without a definition for an individual, unique
outcome, difficulties arise in differentiating one outcome
from another. This results in the reporting of multiple,
apparently different outcomes across studies and impacts
negatively on evidence synthesis thereby contributing to
research waste.
The lack of definition of a unique outcome may also
complicate the development of a core outcome set (COS).
A COS is a minimum set of outcomes that are selected,
measured, and reported in trials of a specific condition
[16]. These are typically developed by identifying all
A.E. Young et al. / Journal of Clioutcomes in the literature and combining these into
groups/domains for stakeholders to prioritize using a
consensus process. The first part of this process requires
that researchers scrutinize the literature and extract out-
comes verbatim for reasons of transparency [8]. Outcomes
are then deduplicated and grouped into individual
‘‘unique’’ outcomes for the prioritization process. The pro-
cess may identify between 20 and more than 1,000 out-
comes [17e20]. This wide variation is likely to reflect
the lack of application of a uniform definition of a unique
outcome, in addition to real differences in numbers of
different outcomes. Guidance as to when the use of
different wording defines the same outcome and when it
does not is lacking; for example, hospital survival and in-
hospital mortality [21,22]. There is no advice as to how
to group similar outcome terms into a single unique
outcome. For example, some researchers may choose to
include all definitions of a specific outcome under one term,
with others seeking more granularity and reporting several
different definitions as unique outcomes [18,23]. There is
no clarity as to which process is correct for demonstrating
variation in outcome reporting and for developing an
outcome long list for a COS. It is also unclear whether
the timing of outcome measurement affects the singularity
of an outcome; for example, some researchers will count
the incidence of wound healing at two specified time points
as two outcomes and others as one [24,25]. Furthermore,
reporting of methods for extracting and grouping outcomes
is often poor. The challenges with identifying and deter-
mining what is a unique outcome means that different re-
searchers may extract a different number of outcomes
from the same data set, and the scale or presence of true
variation in outcome reporting will therefore be difficult
to establish. Inconsistency in methods for extracting out-
comes means that the presence and scale of outcome report-
ing heterogeneity (ORH) is difficult to establish. ORH is a
quantitative measure of the variation in outcomes reported
across trials in one health care area. It is commonly re-
ported in COS development as a number, that is, n 5 x
different outcomes reported across n 5 x trials in a specific
health care area. ORH will impact on the validity of the
long list of outcomes used to inform the consensus pro-
cesses in the development of COSs.
The aim of this article is to examine methods used to
extract, and combine outcomes with the same meaning,
from published research articles to inform how to establish
a reproducible and measurable long list of unique out-
comes. This paper suggests a first working definition of a
unique outcome. A final agreed definition will ensure that
COS researchers can accurately and consistently identify
a quantitative assessment of the inconsistency of outcome
reporting (termed here, ‘‘outcome reported heterogene-
ity’’). We see the enclosed work as a starting point for
debate between international COS researchers, with further
validation before the definitions and methodology being
finalized.
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The study consisted of two phases. Phase 1 was an in-
depth literature review undertaken to analyze and summa-
rize methods for outcome extraction, grouping, defining,
and counting from systematic reviews used to inform
COS development. Phase 2: Findings from phase 1 com-
bined with multidisciplinary expert opinion informed the
development of a first definition of a unique outcome and
methodology for the conversion of outcomes extracted
verbatim from trials into unique outcomes. A first definition
of ORH was developed based on the definition of a unique
outcome.
2.1. Phase one literature review
2.1.1. Data source and search strategy
A structured search of the COMET (Core Outcome
Measures in Effectiveness Trials) database (a repository
of COS studies) was undertaken by two authors (A.E.Y.
and A.D.). As optimal COS development methodology is
still evolving, it was hypothesized that the most current ad-
vances in methodology are likely to be found in recent
studies registered with the COMET database. This database
allows the use of filters to identify the nature of the COS
work (e.g., protocol, full paper, population studies, and so
forth). The filters applied in this study are described in
Appendix A).
2.1.2. Study selection criteria and identification
Titles from the COMET database were used to iden-
tify COS development and related published articles us-
ing Ovid MEDLINE and PubMed [26]. Papers were
included if they met the inclusion criteria below and re-
ported any details of outcome extraction, grouping, and
counting from literature reviews to inform the presence
of ORH and the development of a COS outcome long
list.
Inclusion criteria
 A primary COS development study published be-
tween January 1, 2015 and August 20, 2018;
 A COS protocol (without an associated final COS
published with the above time period); or
 A previously published literature review that was
referenced in, informed, or directly related to a pri-
mary COS published within the aforementioned time
period.
There was no restriction on the type of studies in terms
of patient characteristics or disease area.
2.1.3. Identification of studies
Full text articles were retrieved and reviewed to deter-
mine eligibility, independently and in duplicate by two au-
thors. Reasons for exclusion were ordered hierarchically in
order of importance (Fig. 1) and applied to each full text.Discrepancies were resolved by discussion and consulting
with coauthors. Reference lists of full texts were hand-
searched to identify a comprehensive list of all literature re-
views to support COS development.2.1.4. Data extraction and synthesis
Two authors extracted data using a form developed and
piloted by the study team. Data extracted were as follows:
1 Type of study: primary COS study, COS protocol,
literature review to support a COS;
2 Methodology for extraction and grouping: whether
outcomes were extracted verbatim and methodology
for grouping similar outcomes into unique outcomes.
3 Outcome details: total number of unique outcomes re-
ported (quantitative measure of ORH), presence of
different wording for the same outcomes, and impact
of timing of outcome measurement on numbers of
unique outcomes
Results were compared between researchers, with any
disagreements resolved by a senior COS researcher (J.B.).
Primary COS development studies and their respective
literature review(s) that directly informed the development
of that COS were ‘‘paired’’ for data extraction, so that data
were not duplicated.2.1.5. Data analysis
Numerical data are presented as summary statistics. A
narrative synthesis was applied to methods for extracting
and grouping outcomes from trials and for managing the
timing of outcome assessment [27e29]. Heterogeneity
and similarity of outcome extraction methodology was
noted, exploring relationships between studies.2.2. Phase 2: development of a definition of a unique
outcome and methodology for grouping verbatim
outcomes into unique outcomes
A summary of the findings from phase 1 of the study
were presented to and discussed by a single-center multi-
disciplinary group of senior researchers experienced in
COS research (A.E.Y., A.D., J.M.B., and C.M.; Bristol
Centre for Surgical Research). A first working definition
of a unique trial outcome and methods for conversion of
outcomes extracted verbatim into unique outcomes were
developed, and iteratively refined through further discus-
sion and review of the data from Phase 1. A first definition
for ORH was subsequently proposed, based on the ability to
define a unique outcome. These definitions are a first
attempt to define a unique outcome and to use this to define
ORH. They will be finalized after formal collaboration with
COS developers and the COMET Initiative before
validation.
The study flow chart is illustrated in Fig. 1.
Fig. 1. Study methodology. COMET, Core Outcome Measures in Effectiveness Trials; COS, core outcome set; SRs, systematic review.
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3.1. Phase 1: literature review
The COMET database search yielded 121 titles (seven
duplicates removed) for COS studies. These 121 articles
were identified in OVID Medline and PubMed, and full
texts were then extracted. Hand-searching identified a
further 111 related literature reviews. This led to a total
of 232 studies (Fig. 2). Of these, 100 articles did not reach
the inclusion criteria, leaving 132 studies for data
extraction.
1 Type of study: Of the 132 included studies (Appendix
B), 43 (32.6%) were a final COS, 80 (60.6%) were a
literature review undertaken to support a COS, and
nine (6.8%) were COS protocols with details of a
literature review, where the final COS was not yet
published. Of the final COSs, 30 (69.8%) paired
directly with a previously published literature review,leaving 13 COSs that were analyzed alone. The re-
sults described in the following are therefore taken
from 102 (132-30) different COS studies. Final
numbers of unique outcomes were taken from 93
studies. The 9 protocols were excluded as they would
not report extracted outcome numbers, as detailed in
Fig. 2.
2 Outcome details (Table 1): Thirty-two studies (31.4%)
discussed the issue of the timing of outcome assess-
ment. In 17 (53.2%), these were counted as unique out-
comes (e.g., wound infection at 30 days was reported
as a different outcome to wound infection at 90 days)
based on time alone, whereas the remainder counted
these as just one outcome. Of the 102 studies (with
the nine protocol studies excluded, i.e., n 5 93), 82
(88.1%) reported a quantitative assessment of the num-
ber of outcomes reported across the included trials
(i.e., a quantitative assessment of ORH). The total
number of unique outcomes reported varied from 12
Fig. 2. PRISMA 2009 flow diagram. COMET, Core Outcome Measures in Effectiveness Trials; COS, core outcome set.
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definitions for the same outcome across included trials
were reported in 53 studies (52.0%).
3 Methodology for extraction and grouping (Table 2):
18 studies (17.6%) reported that extraction of out-
comes was verbatim. Of these, only 18, 44% (7.8%
of all 102 studies) included some text description of
the authors’ methodology for grouping these into
unique outcomes (Table 2).Table 1. Outcome details (paired study data collated)
Numbers of studies reporting:
Final numbers of unique outcomes reported across trials within systematic
Researchers state that outcomes were extracted verbatim from trials within
Researchers report different definitions for the same outcome across trials
Researchers report the timing of outcome assessment
Researchers report that the timing of assessment impacts on number of ou
Methodology reported for grouping outcomes into unique outcomes3.2. Phase 2: agreement on methodology for grouping
verbatim outcomes into unique outcomes
Based on the aforementioned data, detailed discussions
were held with a single-center multidisciplinary expert
panel of senior COS researchers regarding the definition
of how a unique outcome should be defined and how this
would impact on the quantitative measure of ORH
(Fig. 3). After iterative refinement, the following definitionNumber of studies (%)
review (excluding protocols, n 5 9) 82/93 (88.1)
systematic review 18/102 (17.6)
within systematic review 53/102 (52.0)
32/102 (31.4)
tcomes reported 17/32 (53.1)
8/18 (44.4)
Table 2. Methodology for identifying outcomes as unique
COS review title Conversion of verbatim outcomes into unique outcomes (text extracted)
A systematic review of outcomes in postoperative pain
studies in paediatric and adolescent patients: towards
development of a core outcome set [30].
‘‘Outcomes were abstracted based on group consensus. We defined an outcome as the
exact word-for-word terms. for any clinical end point, or physiological, metabolic,
or mortality event measured by clinicians or researchers. Final outcomes were then
standardised to improve the consistency of naming. For example, ‘objective pain
score’ was changed to ‘pain measurement.’ After the outcomes had been
standardised, we placed them in broader domains.’’
Evaluating physical activity in dementia: a systematic
review of outcomes to inform the development of a
core outcome set [31].
‘‘From verbatim outcomes to outcome domains: One author, . grouped verbatim
outcomes with the same semantic meaning into outcome domains. For instance, the
verbatim outcomes ‘Functional independence,’ ‘Ability to develop basic activities of
daily living,’ and ‘Functional performance’ were grouped into the outcome domain
‘Functional abilities and independence.’’’
Outcomes mapping study for childhood vaccination
communication: too few concepts were measured
in too many ways [32].
‘‘For each outcome mentioned in an included trial, we extracted into a spreadsheet all
information defining the outcome, such as type., outcome variables., age of the
subjects, and any other related details. We used the exact words of the trial authors.
We did not extract data related to the timing and scale or tool used to measure the
outcomes, as examination of how specific outcome variables were measured was not
the subject of the research. Two researchers reviewed the extracted data. One author
coded the individual outcomes according to what these measured, using the
language of the trialists. These codes were discussed and confirmed. This first round
of codes became the most specific level of the taxonomy. We retained a relatively
large number of different groups rather than aggregating the information and
potentially losing important details.’’
Variability of outcome reporting in Hirschsprung’s
disease and gastroschisis: a systematic
review [23]
‘‘In the 35 included studies, 95 outcomes were investigated a total of 337 times.
Thirty five outcomes were considered to be too similar to at least one other outcome
to be meaningfully differentiated, and these outcomes were therefore mapped to
one common term (e.g., continence/incontinence or frequency of stool/bowel
movement frequency). Following this exercise, 74 unique outcomes were identified
as having been reported. Within the included studies, 102 outcomes were
investigated a total of 247 times. Within these 102 outcomes, there were 63 that
were felt to be too similar to at least one other outcome to be meaningfully
differentiated, and these were therefore mapped to one common term. Following
this mapping process, there remained 62 unique outcomes.’’
No common denominator: a review of outcome
measures in IVF RCTs [33]
‘‘We also did not record outcomes multiple times where these corresponded to
repeated measurements at several time points. For each reported outcome, we
extracted the numerator and denominator (for numerical variables, the denominator
would be the divisor used in the calculation of a mean). Where pregnancy or live
birth were reported, we extracted the corresponding definition used by the study
authors. Data were extracted into two databases, one containing study-level
information and another containing reported-outcome-level information. Due to the
large number of outcomes identified, we reported only those appearing in more than
one study. We simplified the results by combining similar numerators and
denominators. For example, we combined live birth with take home baby rate and
combined the denominators ‘per patient with sufficient embryos’ and ‘per patient
with sufficient blastocysts,’ where ‘sufficiency’ could be defined on the basis of
quantity or quality of embryos (or both). For this primary analysis, we did not
distinguish between subtly different definitions of outcomes (e.g., clinical
pregnancy may have been defined as fetal heartbeat on ultrasound at different time
points in different studies). However, at the suggestion of an anonymous peer
reviewer, we also present the definitions used by trial authors for pregnancy and live
birth outcomes.’’
Systematic review of outcome measures following
chemoradiotherapy for the treatment of anal
cancer (CORMAC) [34].
‘‘Verbatim outcomes were initially reviewed by a single researcher and assigned a
standardized name (‘standardized outcome term’) to overcome variations in wording
used for the same outcome. The standardized outcome term and domain assigned to
each verbatim outcome were reviewed and agreed at a meeting of the CORMAC
Study Advisory Group (SAG), composed of experts in the field of anal cancer,
including clinical oncologists, a colorectal surgeon, radiologist, clinical trials
methodology expert, qualitative research expert, and a patient partner. There were
533 unique terms collapsed into 86 ‘standardized outcome terms,’ representing
outcomes with the same meaning but with differing wording and assigned to the
appropriate outcome domain.’’
(Continued )
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Table 2. Continued
COS review title Conversion of verbatim outcomes into unique outcomes (text extracted)
Outcome reporting in randomized controlled trials
and systematic reviews of gastroschisis treatment:
a systematic review [35]
‘‘We anticipated some diversity in terminology used to report outcomes and therefore
grouped similar outcomes. We identified outcomes that seemed similar or of a
similar theme despite differing definitions used across studies and assigned an
appropriate term to them. For instance, the outcomes ‘proven catheter-related
sepsis (line positive blood cultures necessitating antibiotic treatment or catheter
removal)’ and ‘central line infections’ were included in the term ‘central venous
catheter sepsis.’’’
Developing a core outcome set for fistulising perianal
Crohn’s disease [36]
‘‘Reported outcomes were extracted verbatim and listed in preparation for
categorisation into domains.’’
Abbreviation: RCT, randomized controlled trials.
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that has original meaning and context.’’ Outcomes with
different words, phrasing, or spelling addressing the same
concept and context should be categorized as one outcome.
In other words, researchers should group together outcome
synonyms into one unique outcome term. By the term
‘‘original meaning,’’ individual clinicians and patients
would need to clearly understand what a particular outcome
meant and how it was different to any other outcome. For
example, the number of days in hospital has the same
meaning as hospital length of stay. In terms of ‘‘original
context,’’ we mean that researchers must be clear when
defining the context of the outcome. For example, postop-
erative pain and neuropathic pain would be two different
outcomes as they are different in context. The timing of
outcome measurement should be clearly stated, but an
outcome differing only in this aspect is not unique. Sup-
porting evidence for this is in the fact that outcomes
measured at different time points can be pooled in a
meta-analysis [37]. The definition of ORH is proposed as
‘‘the reporting of multiple unique outcomes across trials
within one health care condition.’’ This relates to the quan-
titative variation in outcomes reported across trials in one
health care area and is dependent on the ability to define
a unique outcome. Both definitions suggested here are
purely suggestions for further discussion and validation.4. Discussion
In this study, we aim to explore through examination of
COS research, what makes one outcome different to any
other outcome. Of all 102 COS studies included in this re-
view, only eight (7.8%) reported any methodological detail
about how verbatim outcomes were grouped into final
unique outcomes. Despite this inability to report how the
final list of different outcomes was determined, authors of
88.1% of studies still reported the final unique outcomes
as a number, that is, they reported variation in outcome re-
porting across studies of one health care area (ORH)
quantitatively.
The number of reported outcomes across studies in this
review varied from 12 to 5,776 (median: 82; IQR: 261). It isunclear why there was such a wide variation in numbers of
different outcomes extracted. We believe the answer lies in
the authors’ decisions regarding the granularity of out-
comes extracted and the use of timing of measurement to
define unique outcomes. Chong et al. in a systematic review
on pediatric chronic kidney disease reported 5,776 different
outcomes from 213 studies [38]. In one group of outcomes,
19 ‘‘unique outcomes’’ all relate to glomerular filtration
rate and were measured at several time pointsdeach of
which was counted as a separate ‘‘unique’’ outcome. This
resulted in 148 apparently unique outcomes in this one
group. Another review used in the development of a COS
on variability in the reporting of renal function endpoints
in immunosuppression trials in renal transplantation re-
ported only 345 outcomes in total (compared to 5,776)
from 213 studies [39]. This review did not include out-
comes measured at different times as unique. Otherwise,
it is not possible to clarify this disparity as neither article
reports how the number of unique outcomes were
calculated.
The timing of outcome assessment was reported in just
less than one-third of studies. Of these studies, more than
half reported outcomes with different times of assessment
as unique. Variation in wording across included trials for
the same outcomes occurred in 53 (52%) of the studies
(e.g., different definitions of wound healing: length of time
to heal to 50% or to 70% healed, time to 90% re-
epithelialization), suggesting that further grouping was
necessary and that these outcomes were not unique. The
lack of methodological detail and significant variation in
numbers of outcomes reported across studies suggests a
nonsystematic approach to outcome extraction and count-
ing. This approach will not allow any true variation in
numbers of outcomes reported across studies to be assessed
accurately (quantitative measure of ORH).
Other authors have previously described, but not
defined, this variation in outcome reporting or ORH
[23,40,41]. They have also described how it leads to prob-
lems in evidence synthesis [23,42,43]. One reason for ORH
is a lack of clarity regarding what constitutes a unique
outcome, what makes one outcome different from another.
Although COSs have been developed to resolve ORH, they
require the extraction of outcomes verbatim from trials, and
Fig. 3. Unique outcome methodology proposal.
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into individual, unique outcomes. This process requires
an understanding of what constitutes a unique outcome
and which outcomes are so similar they can be combined
into one term. It is important to agree the level of granu-
larity required in outcome reporting and this may be
partially responsible for the wide variation in the numbers
of unique outcomes reported.
The COMET Initiative has published analyses of its
COS database [44e47]. This has identified variability in as-
pects of COS development, namely the scope, stakeholder
involvement, and consensus process [44,45,48,49].
COMET has therefore undertaken work to provide method-
ological guidance regarding these aspects of COS develop-
ment [8,46e51]. These activities are extremely useful,
although they have not focused as much on the early partof COS development. The early stages, including extraction
of comprehensive lists of outcomes and identifying the
magnitude of ORH, not only justify the need for a COS
but directly feed into the sets themselves (Fig. 4).
The strengths of this study are that we critically and
systematically analyzed 132 COS development studies,
including 90 systematic reviews used to inform COSs.
A limitation of the study is that we did not undertake a
full systematic review but rather focused our attention
on studies identified through the COMET database from
September 2015, with related articles identified through
two other search engines, as per the published advice on
methodological systematic reviews [49,52]. To support
this approach, Gargon et al. noted the comprehensive na-
ture of the COMET database, in that 720 studies relevant
to the development of COS had been included in the
Fig. 4. Flow chart. ORH, outcome reporting heterogeneity.
22 A.E. Young et al. / Journal of Clinical Epidemiology 115 (2019) 14e24COMET database at the end of December 2015 [46]. In
addition, COSs registered on the COMET database are
likely to be of high quality because of the COMET stan-
dards [8,46]. Finally, we further expanded our search by
including directly related studies identified though two
search engines and hand-searching references. We believe
that it is unlikely that COS development studies reported
before 2015 will describe methodology for the extraction
of unique outcomes if later studies do not. In undertaking
this work, we have not attempted to be comprehensive in
exploring all COS development articles. We wanted to
demonstrate that in a recent group of high-quality COS
research collected in a prespecified manner, no one has
determined objectively and with repeatability how to
extract and count unique outcomes to determine a quanti-
tative measure of ORH across articles in one health care
area.
This study has shown that the process of extracting out-
comes from trials included in COS literature reviews and
grouping the verbatim outcomes into a list of outcomes
that are individual and different (unique) from each other
is complex and poorly reported. Verbatim outcome extrac-
tion is recommended by COMET for reasons of transpar-
ency [8,16]. ‘‘The first step is to group these different
definitions together (extracting the wording description
verbatim) under the same outcome name’’ [8]. Issues with
this include determining when outcomes are the same
even when different words are used; for example, serum
albumin and albumin levels in plasma and how to incorpo-
rate the timing of outcome assessment into this process;
for example, percentage wound healed at 2 weeks and per-
centage wound healed at 6 weeks. If authors could agree
and transparently report how they extracted, grouped,and counted the outcomes reported, a true quantitative
assessment of the true variation in outcome reporting
(ORH) would be possible. A lack of understanding of
what constitutes a unique outcome will impact on the val-
idity of the reported presence and magnitude of ORH as
demonstrated by the widely varying numbers of unique
outcomes reported in the COS literature reviews included
in this study. The other impact is that when outcomes pre-
sented in the later stages of COS development are not
unique it makes prioritization difficult and can hinder
the consensus process.
A final agreed definition for a unique outcome and
methods for objectively grouping outcomes extracted
verbatim into unique outcomes will provide a methodolog-
ical basis for COS developers to define an outcome as
unique and to determine an accurate, quantitative, and
reproducible measure of ORH. The aim of this article is
to start formal discussions between COS researchers and
COMET to raise awareness of this methodological issue
and to undertake collaborative work to refine and validate
a definition for a unique outcome. The answer will allow
researchers to determine a quantitative result for ORH,
how many ‘‘unique’’ outcomes are present across trials in
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